Investigational antiviral drugs for the treatment of COVID-19

C. T.R. Vegivinti; M. Assi; R. Talwani; V. Koblizek; K. Burke; Zelalem Temesgen

doi:10.1358/dof.2021.46.9.3293585

Investigational antiviral drugs for the treatment of COVID-19

C. T.R. Vegivinti, M. Assi, R. Talwani, V. Koblizek, K. Burke, Zelalem Temesgen

Infectious Diseases

Research output: Contribution to journal › Review article › peer-review

Abstract

A large number of candidate drugs are undergoing evaluation for their potential to limit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication. Clinical trial data are slowly emerging for several of these agents. We provide a review of candidate antiviral agents registered in ClinicalTrials.gov, which have clinical efficacy data, provide the rationale for their consideration for this purpose, and summarize available data on their efficacy and safety.

Original language	English (US)
Pages (from-to)	697-710
Number of pages	14
Journal	Drugs of the Future
Volume	46
Issue number	9
DOIs	https://doi.org/10.1358/dof.2021.46.9.3293585
State	Published - Sep 2021

Keywords

COVID-19
Camostat
DAS-181
Favipiravir
Hydroxychloroquine
Ivermectin
Lopinavir/ritonavir
Nafamostat
Nitazoxanide
Remdesivir
Ribavirin
SARS-CoV-2
Umifenovir

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1358/dof.2021.46.9.3293585

Cite this

@article{032d3e59e2c04e07a029b9a81fd4ee4d,

title = "Investigational antiviral drugs for the treatment of COVID-19",

abstract = "A large number of candidate drugs are undergoing evaluation for their potential to limit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication. Clinical trial data are slowly emerging for several of these agents. We provide a review of candidate antiviral agents registered in ClinicalTrials.gov, which have clinical efficacy data, provide the rationale for their consideration for this purpose, and summarize available data on their efficacy and safety.",

keywords = "COVID-19, Camostat, DAS-181, Favipiravir, Hydroxychloroquine, Ivermectin, Lopinavir/ritonavir, Nafamostat, Nitazoxanide, Remdesivir, Ribavirin, SARS-CoV-2, Umifenovir",

author = "Vegivinti, {C. T.R.} and M. Assi and R. Talwani and V. Koblizek and K. Burke and Zelalem Temesgen",

note = "Publisher Copyright: {\textcopyright} 2021 Clarivate Analytics",

year = "2021",

month = sep,

doi = "10.1358/dof.2021.46.9.3293585",

language = "English (US)",

volume = "46",

pages = "697--710",

journal = "Drugs of the Future",

issn = "0377-8282",

publisher = "Prous Science",

number = "9",

}

TY - JOUR

T1 - Investigational antiviral drugs for the treatment of COVID-19

AU - Vegivinti, C. T.R.

AU - Assi, M.

AU - Talwani, R.

AU - Koblizek, V.

AU - Burke, K.

AU - Temesgen, Zelalem

PY - 2021/9

Y1 - 2021/9

N2 - A large number of candidate drugs are undergoing evaluation for their potential to limit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication. Clinical trial data are slowly emerging for several of these agents. We provide a review of candidate antiviral agents registered in ClinicalTrials.gov, which have clinical efficacy data, provide the rationale for their consideration for this purpose, and summarize available data on their efficacy and safety.

AB - A large number of candidate drugs are undergoing evaluation for their potential to limit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication. Clinical trial data are slowly emerging for several of these agents. We provide a review of candidate antiviral agents registered in ClinicalTrials.gov, which have clinical efficacy data, provide the rationale for their consideration for this purpose, and summarize available data on their efficacy and safety.

KW - COVID-19

KW - Camostat

KW - DAS-181

KW - Favipiravir

KW - Hydroxychloroquine

KW - Ivermectin

KW - Lopinavir/ritonavir

KW - Nafamostat

KW - Nitazoxanide

KW - Remdesivir

KW - Ribavirin

KW - SARS-CoV-2

KW - Umifenovir

UR - http://www.scopus.com/inward/record.url?scp=85119151912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85119151912&partnerID=8YFLogxK

U2 - 10.1358/dof.2021.46.9.3293585

DO - 10.1358/dof.2021.46.9.3293585

M3 - Review article

AN - SCOPUS:85119151912

SN - 0377-8282

VL - 46

SP - 697

EP - 710

JO - Drugs of the Future

JF - Drugs of the Future

IS - 9

ER -

Investigational antiviral drugs for the treatment of COVID-19

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this